Delivering timely service and evidence-informed resources to people in BC and the Yukon facing cancer and those involved in oncology care or research.
c.1 BC Cancer Agency ARHCC Library | Available | ||
c.1 BC Cancer Agency SUR Library | Available | ||
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available |
c.1 BC Cancer Agency VIC Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
Table of Contents:; 1. Radiation Dermatitis -- 2. Hair Loss -- 3. Radiation Brain Injury -- 4. Radiation Orbital Toxicity -- 5. Ear Toxicity -- 6. Oral Mucositis -- 7. Xerostomia -- 8. Loss of Taste -- 9. Laryngeal Edema -- 10. Radiation Pneumonitis -- 11. Pericarditis -- 12. Esophagitis -- 13. Ra…
c.1 BC Cancer Agency KEL Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
The IARC Monographs identify environmental factors that are carcinogenic hazards to humans. These include chemicals, complex mixtures, occupational exposures, physical agents, biological agents, and lifestyle factors. National health agencies can use this information as scientific support for their…
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
Volume 1: A-L; Volume 2: M-Z
v.1 BC Cancer Agency VAN Library | Available | ||
v.2 BC Cancer Agency VAN Library | Available |
Volume 1: A-L; Volume 2: M-Z
v.1 BC Cancer Agency VAN Library REF | Available | ||
v.2 BC Cancer Agency VAN Library REF | Available |
This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 2-9 June 2015
Table of Contents; 1: INTRODUCTION TO DOSING MEDICATIONS IN OBESE PATIENTS; 2: ANTIMICROBIAL DOSING IN OBESITY; 3: ANTICOAGULANTS AND ANTIPLATELETS; 4: CRITICAL CARE; 5: ANTIEPILEPTICS; 6: DOSING ANTINEOPLASTIC MEDICATIONS IN OBESE PATIENTS; 7: PEDIATRICS; 8: IMMUNOSUPPRESSION DOSING IN OBESE SOLID…